At Fox Chase Cancer Center, Dr. Elizabeth Plimack and her team have pioneered an innovative approach to bladder preservation in patients with MIBC. Through clinical trials like RETAIN-1 and RETAIN-2, they are challenging traditional treatment paradigms by exploring systemic therapy-based strategies as alternatives to radical cystectomy and trimodality therapy.
In this exclusive interview, Dr. Plimack discusses the development of the RETAIN approach, from early findings with neoadjuvant ddMVAC to the evolution of the concept in the RETAIN-1 and RETAIN-2 trials. She also shares insights into the design of the upcoming RETAIN-3 trial.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.